Nanotechnology Now - Press Release: Iron Nanoparticles Spot Tumor Spread in Patients With Kidney Cancer

Home > Press > Iron Nanoparticles Spot Tumor Spread in Patients With Kidney Cancer

Abstract:
Iron nanoparticles designed to collect in lymph nodes containing metastatic cancer cells have proven that they can help physicians detect metastatic spread of prostate cancer. Now, a team of investigators at Harvard Medical School has pilot phase data showing that these nanoparticles can detect lymph node metastases in a highly sensitive and specific manner in patients with renal cell carcinoma, which accounts for some 20% of kidney cancers.

Iron Nanoparticles Spot Tumor Spread in Patients With Kidney Cancer

Bethesda , MD | Posted on April 19th, 2008

Reporting its work in the journal Oncology, a team of researchers headed by Alexander Guimaraes, M.D., Ph.D., Mukesh Harisinghani, M.D., and Ralph Weissleder, M.D., who is the principal investigator of the MIT-Harvard Center for Cancer Nanotechnology Excellence, showed that dextran-coated iron oxide administered to nine patients with kidney tumors could clearly identify lymph node metastases and distinguish them from benign lesions using magnetic resonance (MR) imaging. These results were confirmed by traditional histopathology techniques, revealing one false-positive among the MR imaging results. MR imaging of lymph nodes did not miss detecting any metastases later identified by histopathology. The researchers conclude that these studies warrant a larger, prospective clinical trial to prove that iron oxide nanoparticles can serve as a noninvasive diagnostic for metastatic disease.

####

About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: